Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS
NCT04643691 · Assistance Publique Hopitaux De Marseille · PHASE2 · terminated · last registry update 2024-06-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “due to an Urgent Security Measure” | – | Registry record, Assistance Publique Hopitaux De Marseille |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AGTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-06-04Also stopped (terminated): University of Arizona, Angiotensin-(1-7) + Placebo for Angiotensin-(1-7) (NCT03252093)
- 2025-06-04Also stopped (suspended): University of Arizona, Angiotensin-(1-7) (NCT03159988)
- 2025-06-03Results posted on the registry: University of Iowa, Salsalate Oral Tablet + Placebo Oral Tablet (NCT03482440)
- 2025-02-25Results posted on the registry: Arbor Pharmaceuticals, Inc., Azilsartan Medoxomil Low-dose + Losartan (NCT02235909)
- 2025-02-18Results posted on the registry: Ionis Pharmaceuticals, Inc., Placebo + IONIS-AGT-LRx (NCT04714320)
- 2025-01-31Results posted on the registry: Vicore Pharma AB, C106 solution + Placebo (NCT05427253)
- 2025-01-22Results posted on the registry: Sean Collins, TXA127 + TRV027 (NCT04924660)
- 2024-12-31Results posted on the registry: Anna Stanhewicz, PhD, Compound 21 + Compound 21 + losartan (NCT05576155)
- 2024-12-27Results posted on the registry: Alnylam Pharmaceuticals, Placebo + ALN-AGT01 (NCT04936035)
- 2024-12-27Also stopped (withdrawn): Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Losartan + Gemcitabine (NCT05861336)
- 2024-12-09Results posted on the registry: Takeda, TAK-536 (NCT04668157)
- 2024-11-12Results posted on the registry: Vicore Pharma AB, C21 (NCT05831644)
- 2024-10-17Phase 3 first posted: Hyundai Pharm, Ezetimibe/Rosuvastatin/Candesartan/Amlodipine + Candesartan/Amlodipine (NCT06646354)
- 2024-09-27Results posted on the registry: Pfizer, losartan + dextromethorphan (NCT03864042)
- 2024-09-26Phase 3 first posted: Universität Münster, Angiotensin II + Noradrenalin (NCT06615102)
- 2024-09-23Phase 3 first posted: Eurofarma Laboratorios S.A., N0877 + Benicar HCT ® Tablets 40 mg/25 mg (NCT06608472)
- 2024-09-23Also stopped (withdrawn): NYU Langone Health, Losartan (NCT06333522)
- 2024-09-04Results posted on the registry: Alexander Flannery, Angiotensin II (NCT04558359)
- 2024-08-15Also stopped (terminated): Organon and Co, MK0954, losartan potassium / Duration of Treatment - 12 weeks (NCT00449111)
- 2024-08-02Results posted on the registry: University of Kansas Medical Center, Losartan (NCT04335123)
- 2024-07-16Results posted on the registry: University of Wisconsin, Madison, Anti-Hypertensive (NCT05479097)
- 2024-07-03Results posted on the registry: Travere Therapeutics, Inc., sparsentan + irbesartan (NCT03762850)
- 2024-06-18Also stopped (terminated): Organon and Co, hydrochlorothiazide (+) losartan potassium + losartan potassium (NCT00447603)
- 2024-06-10Also stopped (terminated): Amy Arnold, Angiotensin-(1-7) + Saline (NCT03604289)
- 2024-05-03Also stopped (terminated): Milton S. Hershey Medical Center, Angiotensin 1-7 + Saline (NCT03240068)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision